Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Inventiva ( (IVA) ) has shared an announcement.
On March 30, 2026, Inventiva reported its 2025 results, highlighting revenues of €4.5 million, cash and cash equivalents of €99.3 million plus €131.6 million in short‑term deposits as of December 31, 2025, and a widened net loss of €354.1 million driven largely by non‑cash financial charges. The company strengthened its balance sheet via a $172.5 million U.S. equity offering and the second tranche of a structured financing, completed the sale of odiparcil with potential future milestones, and now expects its cash runway to extend into mid‑Q1 2027, while refining the timing of topline NATiV3 Phase 3 MASH data to the fourth quarter of 2026, underscoring both the financing risk and the strategic focus on bringing lanifibranor to market.
R&D spending fell 4% to €87.0 million as Inventiva prioritized lanifibranor and completed enrollment in the NATiV3 trial in April 2025, but G&A costs rose sharply to €47.9 million, largely due to share‑based compensation tied to governance and organizational changes. The board approved the 2025 accounts on March 27, 2026, and auditors will flag a material uncertainty related to going concern, highlighting that despite solid liquidity today and optional upside from warrant exercises and odiparcil milestones, investors remain exposed to execution and financing risks pending the key Phase 3 data readout.
The most recent analyst rating on (IVA) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Inventiva stock, see the IVA Stock Forecast page.
Spark’s Take on IVA Stock
According to Spark, TipRanks’ AI Analyst, IVA is a Neutral.
The score is held down primarily by weak financial performance (ongoing losses, negative equity, and negative operating/free cash flow). Technicals provide a meaningful offset due to a clear uptrend and positive momentum, while valuation remains unfavorable given the loss-making profile and no dividend support.
To see Spark’s full report on IVA stock, click here.
More about Inventiva
Inventiva S.A. is a clinical‑stage biopharmaceutical company listed on Euronext Paris and Nasdaq, specializing in oral therapies for metabolic dysfunction‑associated steatohepatitis (MASH). Its lead product candidate, lanifibranor, targets MASH, and the company is building regulatory and commercial infrastructure in anticipation of potential commercialization.
Average Trading Volume: 433,126
Technical Sentiment Signal: Buy
Current Market Cap: $1.19B
For detailed information about IVA stock, go to TipRanks’ Stock Analysis page.